As biologics grow larger and more complex — from plasmid DNA and viral vectors to mRNA and monoclonal antibodies — traditional resin columns are falling behind. Membrane chromatography replaces slow, diffusion-based binding with rapid convective flow, cutting cycle times from hours to minutes while simplifying scale-up and supply chains. It's fast becoming the purification platform of choice for next-generation therapies.

Discover why traditional resin chromatography is falling short for advanced biologics purification. As the biopharmaceutical industry evolves, membrane chromatography offers faster cycle times, better scalability, and lower costs — with the market projected to reach $959.42M by 2032

As mRNA, saRNA, and plasmid DNA therapies move from breakthrough to broad clinical adoption, traditional resin and monolith chromatography are hitting their limits — struggling with size, shear sensitivity, and throughput. Next-generation membrane chromatography offers a faster, gentler, more scalable path forward for nucleic acid purification.

After four years of building our future under Donaldson, we’re retiring the Purilogics name and moving forward as Purexa, supported by our company identity, Donaldson Life Sciences.

This interview features: Jin Zhou, Co-Founder, Business Leader, Purilogics By Donaldson, from BioProcess International 2023.

Purilogics’ Jinxiang Zhou recently co-authored an article alongside Camila Leal-Lopes, Sara D’Angelo, Andre A.R. Teixeira, Andrew R.M Bradbury, Fortunato Ferrara, and M. Frank Erasmus – the Head of Bioinformatics at Specifica, Inc. We are excited to announce that this article has been published in the New Biotechnology Journal: High throughput purification of monoclonal recombinant antibodies using a Protein-A coated membrane plate system.

Gene therapy involves the manipulation of gene expression pathways in cells utilized in the treatment of both genetic and pathological diseases. The delivery of genetic-based material, such as RNA or DNA, to cells modifies their expression patterns.

Recent developments in research have highlighted the potential of non-viral nanoparticles as vectors in gene therapy. Gene therapy typically refers to the use of nucleic acids, such as plasmids and siRNA, to genetically modify patient’s cells.1 Traditionally, viral vectors have been pursued as gene delivery vehicles, but a variety of risks and problems associated with them have limited their large-scale use clinically.

Recent developments have made small-scale antibody expression much easier. Upstream scientists can express tens or hundreds of antibodies in parallel. Analysis of purified samples at early stage will likely improve long-term success rate because there will be a reduction in interference of impurities.

In vitro-transcribed (IVT) mRNA is an alternative genetic material that can be used in the replacement of plasmid DNA in conventional uses…

How can Purilogics help? We offer membrane columns for small-scale antibody purification. Our mini and midi columns can be used with a syringe to purify small volumes of antibody.

Over the past few years, we have seen a steady increase in the demand for plasmid DNA, as the gene and cell therapy industries have experienced rapid growth…

Hydrophobic interaction chromatography (HIC) separates molecules based on differences in their hydrophobicity. It is an important technique in both sample analysis and preparative scale purification…

mRNA impurities need to be removed to achieve high potency and safety throughout the production process. mRNA production begins with plasmid DNA, which then needs to be linearized.

Purilogics offers a wide variety of differentiated products for your purification needs. Here are some highlights on the uniqueness of our membrane chromatography products:..

Fast protein liquid chromatography (FPLC) is a common purification technique used widely in various biologics preparation. Often, we complain how slow chromatography columns are, but we have ignored that FPLC itself can cause more trouble than it is worth.

Over the past 18 months, there has been a sharp rise in interest concerning the development of mRNA-based therapies, as highlighted by the FDA’s Emergency Use Authorization and subsequent approval of one of two novel SARS-CoV-2 mRNA vaccines.

A key focus of Purilogics is to emphasize the drastic decrease in processing time when using our membranes for biologics purification…

Imagine a glass holding sugar. After adding water, it is left to sit. Ultimately, the sugar will dissolve after a few hours…

At Purilogics, we take pride in designing and developing membrane chromatography technologies for biologics purification. Our mission is to provide rapid and effective purification solutions to help the biopharmaceutical industry simplify biologics purification.